Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lichtlen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Neurochemistry|November 8, 2007
Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical toolsPeter Lichtlen, M Hasan Mohajeri
Clinical Pediatrics|May 11, 2018
Unmet Needs in Pediatric Functional ConstipationManu Sood, Peter Lichtlen, Maria Claudia Perez
Biochimica Et Biophysica Acta|July 26, 2003
Cell growth selection system to detect extracellular and transmembrane protein interactionsDavid M Urech, Peter Lichtlen, Alcide Barberis
Journal of Clinical Gastroenterology|June 23, 2020
Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced ConstipationSatish S C Rao, Peter Lichtlen, Sepideh Habibi
Investigative Ophthalmology & Visual Science|September 2, 2008
Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancerMichael Ottiger, Michael A Thiel, Ulrich Feige, et al.
Pharmacoeconomics - Open|January 6, 2018
The Cost Effectiveness of Lubiprostone in Chronic Idiopathic ConstipationBecky Pennington, Emily-Ruth Marriott, Peter Lichtlen, et al.
Investigative Ophthalmology & Visual Science|April 16, 2010
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105Peter Lichtlen, Tim T Lam, T Michael Nork, et al.
Pain Medicine (Malden, Mass.)|June 14, 2018
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid ClassLynn R Webster, Randall P Brewer, Peter Lichtlen, et al.
Investigative Ophthalmology & Visual Science|September 2, 2008
Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eyeEsther Furrer, Marianne Berdugo, Cinzia Stella, et al.
Advances in Therapy|May 24, 2021
Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional ConstipationAtoya Adams, Charles Barish, Angel Chen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Neurochemistry|November 8, 2007
Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical toolsPeter Lichtlen, M Hasan Mohajeri
Clinical Pediatrics|May 11, 2018
Unmet Needs in Pediatric Functional ConstipationManu Sood, Peter Lichtlen, Maria Claudia Perez
Biochimica Et Biophysica Acta|July 26, 2003
Cell growth selection system to detect extracellular and transmembrane protein interactionsDavid M Urech, Peter Lichtlen, Alcide Barberis
Journal of Clinical Gastroenterology|June 23, 2020
Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced ConstipationSatish S C Rao, Peter Lichtlen, Sepideh Habibi
Investigative Ophthalmology & Visual Science|September 2, 2008
Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancerMichael Ottiger, Michael A Thiel, Ulrich Feige, et al.
Pharmacoeconomics - Open|January 6, 2018
The Cost Effectiveness of Lubiprostone in Chronic Idiopathic ConstipationBecky Pennington, Emily-Ruth Marriott, Peter Lichtlen, et al.
Investigative Ophthalmology & Visual Science|April 16, 2010
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105Peter Lichtlen, Tim T Lam, T Michael Nork, et al.
Pain Medicine (Malden, Mass.)|June 14, 2018
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid ClassLynn R Webster, Randall P Brewer, Peter Lichtlen, et al.
Investigative Ophthalmology & Visual Science|September 2, 2008
Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eyeEsther Furrer, Marianne Berdugo, Cinzia Stella, et al.
Advances in Therapy|May 24, 2021
Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional ConstipationAtoya Adams, Charles Barish, Angel Chen, et al.
Pageof 2